Tokyo, Japan

Hiroki Kurihara


Average Co-Inventor Count = 5.8

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 1991-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Hiroki Kurihara: Innovator in Vasoconstrictor Peptides

Introduction

Hiroki Kurihara is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of vasoconstrictor peptides. With a total of 2 patents, his work has implications for therapeutic agents in treating hypotension.

Latest Patents

One of Kurihara's latest patents is focused on a mouse with defective endotheline-1 gene function. This invention relates to a vasoconstrictor peptide known as Endothelin, which has a molecular weight of 2,500 ± 300. Endothelin consists of 21 amino acid residues, with four cysteines forming two sets of S--S bonds. To obtain the vasoconstrictor factors, it is preferable to culture endothelial cells collected from the vascular inner walls in a serum-free medium. The peptides developed can be utilized as hypotension therapeutic agents or local vasoconstrictors for animals, including humans.

Career Highlights

Throughout his career, Hiroki Kurihara has worked with prominent companies such as Chugai Seiyaku Kabushiki Kaisha and Takeda Chemical Industries, Ltd. His experience in these organizations has contributed to his expertise in the field of peptide research and development.

Collaborations

Kurihara has collaborated with notable individuals in his field, including Yoshio Yazaki and Yukiko Kurihara. These collaborations have likely enhanced his research and innovation capabilities.

Conclusion

Hiroki Kurihara's contributions to the field of vasoconstrictor peptides demonstrate his innovative spirit and dedication to biomedical research. His patents and collaborations reflect a commitment to advancing therapeutic solutions for health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…